Fairfax, VANCT06805825Now EnrollingIRB Ready

Gastrointestinal Stromal Tumors Clinical Trial in Fairfax, VA

Access cutting-edge gastrointestinal stromal tumors treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.

Sponsored by Novelty Nobility, Inc.

Quick Self-Assessment

See if you qualify for this Fairfax location

Preparing your pre-screening questions…

Expert Care in Fairfax

Access gastrointestinal stromal tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastrointestinal stromal tumors treatment provided free

Apply for This Fairfax Location

Check if you qualify for this gastrointestinal stromal tumors clinical trial in Fairfax, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairfax

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairfax site if eligible
  4. 4Begin participation

About This Gastrointestinal Stromal Tumors Study in Fairfax

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

Sponsor: Novelty Nobility, Inc.

Who Can Participate

Inclusion Criteria

Subjects must meet the following criteria to be eligible for enrollment into the study:
Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC.
Subjects must have received the following treatment: Part A (Dose Escalation): i. Treatment with imatinib for GIST (at least one line of therapy with imatinib) or ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET ChRCC or ccRCC) Part B (Dose Expansion): i. Treatment with imatinib for GIST (at least one line of therapy with imatinib) or ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for Extensive stage SCLC or iii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET or ChRCC or ccRCC).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 3 months before starting NN3201 in the opinion of the Investigator.
Age ≥ 18 years.
Laboratory values demonstrating adequately functioning kidney, liver and bone marrow (hematology).
Adequate heart function as measured by ECHO/MUGA scan.
Time between prior anticancer therapy including investigational agents and first dose of NN3201 as below:
Cytotoxic chemotherapy - At least 21 days
Non-cytotoxic chemotherapy (e.g., small molecule inhibitor) - At least 14 days
Nitrosoureas - At least 6 weeks
Monoclonal antibody(ies) - At least 28 days
Radiotherapy - At least 14 days from local site radiation therapy
Negative Serum/urine pregnancy test (for subjects of childbearing potential)
All subjects of childbearing potential must agree to use contraception throughout the study and for additional 120 days after the last dose of assigned treatment. Subjects must refrain from donating sperm during the same period or Subjects who do not have childbearing potential are confirmed post-menopausal or sterile.
Voluntary agreement to provide written informed consent and have willingness and ability to comply with all aspects of the protocol. Key

Exclusion Criteria

Has received prior therapy with a c-Kit agent (except GIST subjects).
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms.
A condition requiring systemic treatment with corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to administration of study drugs (inhaled corticosteroids are allowed).
Any prior treatment-related (i.e., chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at Study Entry, Day -2 to Cycle 1 Day 1.
Major surgery within 30 days before the first dose of study drug treatment in Cycle 1 on Day 1 (port placement for venous access is not considered major surgery).
Significant cardiovascular impairment.
Significant screening electrocardiogram (ECG) abnormalities.
Known active and clinically significant bacterial, fungal, or viral infection.
Uncontrolled hypertension defined as systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg, despite optimal medical management.
Venous thrombosis or pulmonary embolism within the last 3 months prior to the screening.
Ongoing or active infection requiring intravenous treatment with anti-infective therapy or systemic therapy and/or any identified active COVID-19 infection.
Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
People who are pregnant or breastfeeding. Other inclusion and exclusion criteria must also be met to be eligible to participate in this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT06805825) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastrointestinal Stromal Tumors Treatment Options in Fairfax, VA

If you're searching for gastrointestinal stromal tumors treatment options in Fairfax, VA, this clinical trial (NCT06805825) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastrointestinal stromal tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastrointestinal stromal tumors clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Fairfax, VA

See all ankylosing spondylitis clinical trials recruiting in Fairfax — not just this study.

Browse Ankylosing Spondylitis Trials in Fairfax →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Fairfax?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairfax, VA